NVOS — Novo Integrated Sciences Share Price
0.000.00%
Last trade - 00:00- $0.05m
- $3.06m
- $13.29m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -57.38% | ||
| Return on Equity | -81.43% | ||
| Operating Margin | -75.79% | ||
Financial Summary
| Year End 31st Aug | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 7.86 | 9.31 | 11.74 | 12.57 | 13.29 | n/a | n/a | 7.13% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Novo Integrated Sciences, Inc. owns Canadian and United States subsidiaries which provide, or intend to provide, essential and differentiated solutions to the delivery of multidisciplinary primary care and related wellness products through the integration of medical technology, interconnectivity, advanced therapeutics, diagnostic solutions, personalized product offerings, and rehabilitative science. It operates through two reportable segments: healthcare services and product sales. Its businesses include healthcare, medical technology, manufacturing, research and diagnostics, and products and brands. Its specialized primary health care services include physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, and others. Its products include Terragenx and ProDip (dietary supplement pouches). Terragenx is a micro-dosing IoNovo Iodine product for all ages and lifestyles. Its medical technologies include telemedicine, and remote patient monitoring.
Directors
- Robert Mattacchione CHM (53)
- Christopher David PRE (62)
- James Zsebok CFO (55)
- Michael Gaynor SEC (55)
- Pierre Dalcourt DRC (51)
- Alex Flesias IND (47)
- Robert Oliva IND (58)
- Michael Pope IND (41)
- Last Annual
- August 31st, 2024
- Last Interim
- August 31st, 2024
- Incorporated
- February 20th, 2008
- Public Since
- July 12th, 2005
- No. of Shareholders
- 550
- No. of Employees
- 115
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 19,730,247
- Address
- 11120 NE 2ND STREET, SUITE 100, BELLEVUE, 98004
- Web
- https://www.novointegrated.com/
- Phone
- +1 2066179797
- Contact
- Christopher David
- Auditors
- Fruci & Associates II,PLLC
Upcoming Events for NVOS
Similar to NVOS
4Cable TV International
Pink Sheets on Nasdaq
Abattis Bioceuticals
Pink Sheets on Nasdaq
Accelera Innovations
Pink Sheets on Nasdaq
Quantum Medical Transport
Pink Sheets on Nasdaq
Aesthetic Medical International Holdings
Pink Sheets on Nasdaq
FAQ
What is the Novo Integrated Sciences share price?
As of Today at 22:21 UTC, shares in Novo Integrated Sciences are trading at $0.00. This share price information is delayed by 15 minutes.
How has the Novo Integrated Sciences share price performed this year?
Shares in Novo Integrated Sciences last closed at $0.00 and the price had moved by -99.51% over the past 365 days. In terms of relative price strength the Novo Integrated Sciences share price has underperformed the S&P500 Index by -99.54% over the past year.
What are the analyst and broker recommendations for Novo Integrated Sciences?
There is no consensus recommendation for this security.
Find out moreWhat is the Novo Integrated Sciences dividend yield?
Novo Integrated Sciences does not currently pay a dividend.
Does Novo Integrated Sciences pay a dividend?
Novo Integrated Sciences does not currently pay a dividend.
When does Novo Integrated Sciences next pay dividends?
Novo Integrated Sciences does not currently pay a dividend.
How do I buy Novo Integrated Sciences shares?
To buy shares in Novo Integrated Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Novo Integrated Sciences?
As of the previous close price of $0.00, shares in Novo Integrated Sciences had a market capitalisation of $0.05m.
Where are Novo Integrated Sciences shares listed?
Here are the trading details for Novo Integrated Sciences:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: NVOS
What kind of share is Novo Integrated Sciences?
Based on an overall assessment of its quality, value and momentum Novo Integrated Sciences is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Novo Integrated Sciences share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Novo Integrated Sciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Novo Integrated Sciences. Over the past six months, its share price has underperformed the S&P500 Index by -98.81%.
As of the last closing price of $0.00, shares in Novo Integrated Sciences were trading -98.82% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Novo Integrated Sciences PE Ratio?
The Novo Integrated Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Novo Integrated Sciences?
Novo Integrated Sciences' management team is headed by:
- Robert Mattacchione - CHM
- Christopher David - PRE
- James Zsebok - CFO
- Michael Gaynor - SEC
- Pierre Dalcourt - DRC
- Alex Flesias - IND
- Robert Oliva - IND
- Michael Pope - IND